The FCF Healthcare & Life Sciences Venture Capital Monitor – Europe is a monthly overview of financing trends in the venture capital sector, with a focus on European healthcare and life sciences companies.
Total Healthcare & Life Sciences funding reached EUR 6,158m (-5% vs. 2025)
Biotech/Pharma received 36% of the total investment volume (EUR 2,227m), with oncology being the leading indication (37%)
In June, Bionyra (FR) secured the highest transaction volume with EUR 143m, followed by RQ Bio (UK) with EUR 99m and Ona Therapeutics (ES) with EUR 74m
GV (US) is the most active investor (by deal volume in 2026), followed by Alphabet (US) and CapitalG (US)
To read the full report, click here.